|Other names||SKL-N05, ADX-N05, ARL-N05, YKP10A, R228060, and JZP-110; (R)-2-amino-3-phenylpropylcarbamate hydrochloride|
|Drug class||Norepinephrine–dopamine reuptake inhibitor|
|Main uses||Excessive sleepiness from narcolepsy or obstructive sleep apnea|
|Side effects||Headache, nausea, anxiety, trouble sleeping|
|Elimination half-life||~7.1 hours|
|Excretion||Urine (95% unchanged)|
|Chemical and physical data|
|Molar mass||194.234 g·mol−1|
|3D model (JSmol)|
Common side effects include headache, nausea, anxiety, and trouble sleeping. Other side effects may include increased blood pressure and abuse. It interacts with monoamine oxidase (MAO) inhibitors. Safety in pregnancy and breastfeeding is unclear. It is a norepinephrine–dopamine reuptake inhibitor (NDRI); though how it improves wakefulness is not entirely clear.
Solriamfetol was approved for medical use in the United States in 2019 and Europe in 2020. In the United States its costs about 690 USD per month as of 2021. In the United States it is a Schedule IV controlled substance.
It is taken at a dose of 37.5 to 150 mg once per day.
Solriamfetol is a norepinephrine–dopamine reuptake inhibitor (NDRI). It binds to the dopamine transporter and the norepinephrine transporter with affinities (Ki) of 14.2 μM and 3.7 μM, respectively). It inhibits the reuptake of dopamine and norepinephrine with IC50 values of 2.9 μM and 4.4 μM, respectively. It has weak affinity for the serotonin transporter (Ki = 81.5 μM) and does not appreciably inhibit serotonin reuptake (IC50 > 100 μM). Solriamfetol has no appreciable affinity for a variety of other targets, including the dopamine, serotonin, adrenergic, GABA, adenosine, histamine, orexin, benzodiazepine, and acetylcholine receptors.
The drug was discovered by a subsidiary of SK Group, which licensed rights outside of eleven countries in Asia to Aerial Pharma in 2011. Aerial ran two Phase II trials of the drug in narcolepsy before selling the license to solriamfetol to Jazz in 2014; Jazz Pharmaceuticals paid Aerial $125 million up front and will pay Aerial and SK up to $272 million in milestone payments, and will pay double-digit royalties to SK.
The U.S. Food and Drug Administration (FDA) approved solriamfetol based primarily on evidence from five clinical trials (Trial 1/NCT02348593, Trial 2/NCT02348606, Trial 3/NCT02348619, Trial 4/NCT02348632, Trial 5 NCT01681121) of 622 patients with narcolepsy or obstructive sleep apnea (OSA). The trials were conducted in Canada, Europe, and the United States.
Solriamfetol was approved for medical use in the European Union in January 2020.
Society and culture
During development it has been called SKL-N05, ADX-N05, ARL-N05, and JZP-110.
In the United States, solriamfetol is a Schedule IV controlled substance, meaning that it has an accepted medical use and a low potential for abuse, but that abuse may lead to physical or psychological dependence. A prescription is required, and can only be refilled up to five times in a six-month period. In countries of the European Union, a prescription is required.
- "Sunosi- solriamfetol tablet, film coated". DailyMed. 16 October 2019. Archived from the original on 7 August 2020. Retrieved 24 November 2019.
- "Solriamfetol Monograph for Professionals". Drugs.com. Archived from the original on 4 March 2021. Retrieved 14 October 2021.
- "Sunosi EPAR". European Medicines Agency (EMA). 12 November 2019. Archived from the original on 8 November 2020. Retrieved 26 September 2020.
- "Solriamfetol (Sunosi) Use During Pregnancy". Drugs.com. Archived from the original on 26 October 2020. Retrieved 14 October 2021.
- "Sunosi". Archived from the original on 8 November 2020. Retrieved 14 October 2021.
- "Sunosi Prices, Coupons & Savings Tips - GoodRx". GoodRx. Archived from the original on 27 December 2021. Retrieved 14 October 2021.
- Abad VC, Guilleminault C (2017). "New developments in the management of narcolepsy". Nature and Science of Sleep. 9: 39–57. doi:10.2147/NSS.S103467. PMC 5344488. PMID 28424564.
- Ji-young S (5 March 2018). "SK Biopharmaceuticals' narcolepsy drug on track to hitting US market". The Korea Herald. Archived from the original on 16 April 2018. Retrieved 10 June 2021.
- Sullivan SS, Guilleminault C (2015). "Emerging drugs for common conditions of sleepiness: obstructive sleep apnea and narcolepsy". Expert Opinion on Emerging Drugs. 20 (4): 571–82. doi:10.1517/14728214.2015.1115480. PMID 26558298. S2CID 7951307.
- Garde D (14 January 2014). "Jazz bets up to $397M on Aerial's narcolepsy drug". FierceBiotech. Archived from the original on 20 October 2020. Retrieved 10 June 2021.
- "Drug Trials Snapshots: Sunosi". U.S. Food and Drug Administration (FDA). 16 April 2019. Archived from the original on 28 September 2019. Retrieved 24 November 2019. This article incorporates text from this source, which is in the public domain.
- "Drug Approval Package: Sunosi". U.S. Food and Drug Administration (FDA). 29 April 2019. Archived from the original on 24 November 2019. Retrieved 24 November 2019. This article incorporates text from this source, which is in the public domain.
- "Solriamfetol Orphan Drug Approval". U.S. Food and Drug Administration (FDA). Archived from the original on 24 November 2019. Retrieved 24 November 2019. This article incorporates text from this source, which is in the public domain.
- "Solriamfetol - Jazz Pharmaceuticals/SK Biopharmaceuticals". AdisInsight. Archived from the original on 1 September 2017. Retrieved 15 April 2018.
- 21 U.S.C. § 812 – Schedules of controlled substances
- "Manuals – Practitioner's Manual – SECTION V". Archived from the original on 7 January 2014. Retrieved 10 June 2021. Retrieved 2014-01-07